BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 29169614)

  • 1. Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study.
    Dong L; Wang MZ; Zhao XL; Feng RM; Hu SY; Zhang Q; Smith JS; Qiao YL; Zhao FH
    Gynecol Oncol; 2018 Jan; 148(1):103-110. PubMed ID: 29169614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.
    Song F; Du H; Wang C; Huang X; Wu R;
    PLoS One; 2020; 15(6):e0234518. PubMed ID: 32525936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic accuracy of high-risk HPV DNA genotyping for primary cervical cancer screening and triage of HPV-positive women, compared to cytology: preliminary results of the PIPAVIR study.
    Chatzistamatiou K; Moysiadis T; Angelis E; Kaufmann A; Skenderi A; Jansen-Duerr P; Lekka I; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Tsertanidou A; Koch I; Boecher O; Soutschek E; Maglaveras N; Agorastos T
    Arch Gynecol Obstet; 2017 May; 295(5):1247-1257. PubMed ID: 28337594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy.
    Dijkstra MG; van Niekerk D; Rijkaart DC; van Kemenade FJ; Heideman DA; Snijders PJ; Meijer CJ; Berkhof J
    Cancer Epidemiol Biomarkers Prev; 2014 Jan; 23(1):55-63. PubMed ID: 23733907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Performance of vaginal self-sampling high-risk HPV genotyping as primary and combining cytology or viral load as secondary in cervical cancer screening].
    Guo CL; Luo HX; Wang C; Qu XF; Yang B; Belinson JL; Du H; Wu RF
    Zhonghua Fu Chan Ke Za Zhi; 2021 Apr; 56(4):271-279. PubMed ID: 33902239
    [No Abstract]   [Full Text] [Related]  

  • 7. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
    Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
    BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Viral Load as a Triage Strategy With Primary High-Risk Human Papillomavirus Cervical Cancer Screening.
    Luo H; Belinson JL; Du H; Liu Z; Zhang L; Wang C; Qu X; Pretorius RG; Wu R
    J Low Genit Tract Dis; 2017 Jan; 21(1):12-16. PubMed ID: 27851695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
    Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
    Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology.
    Castle PE; Reid J; Dockter J; Getman D
    J Clin Virol; 2015 Aug; 69():52-5. PubMed ID: 26209379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High performance of combined HPV testing and genotyping for HPV16/18/52/58 in triaging women with minor cervical cytological abnormalities in northern Thailand.
    Khunamornpong S; Settakorn J; Sukpan K; Srisomboon J; Intaraphet S; Siriaunkgul S
    J Med Virol; 2016 Jan; 88(1):135-43. PubMed ID: 26129775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
    Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
    Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan.
    Chang CL; Ho SC; Su YF; Juan YC; Huang CY; Chao AS; Hsu ZS; Chang CF; Fwu CW; Chang TC
    Gynecol Oncol; 2021 May; 161(2):429-435. PubMed ID: 33757653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology.
    Thomsen LT; Frederiksen K; Munk C; Junge J; Iftner T; Kjaer SK
    Int J Cancer; 2015 Jul; 137(1):193-203. PubMed ID: 25471319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of cytology, HPV DNA testing and HPV 16/18 genotyping alone or combined targeting to the more balanced methodology for cervical cancer screening.
    Chatzistamatiou K; Moysiadis T; Moschaki V; Panteleris N; Agorastos T
    Gynecol Oncol; 2016 Jul; 142(1):120-127. PubMed ID: 27126005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The application of BMRT-HPV viral load to secondary screening strategies for cervical cancer.
    Duan L; Du H; Wang C; Huang X; Qu X; Shi B; Liu Y; Zhang W; Duan X; Wei L; Belinson JL; Wu R
    PLoS One; 2020; 15(5):e0232117. PubMed ID: 32357165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial.
    Zhang J; Zhao Y; Dai Y; Dang L; Ma L; Yang C; Li Y; Kong L; Wei L; Zhang S; Liu J; Xi M; Chen L; Duan X; Xiao Q; Abulizi G; Zhang G; Hong Y; Gao X; Zhou Q; Xie X; Li L; Niyazi M; Zhang Z; Tuo J; Ding Y; Si M; Chen F; Song L; Qiao Y; Lang J
    JAMA Oncol; 2021 Feb; 7(2):263-270. PubMed ID: 33377903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus viral load expressed as relative light units (RLU) correlates with the presence and grade of preneoplastic lesions of the uterine cervix in atypical squamous cells of undetermined significance (ASCUS) cytology.
    Origoni M; Carminati G; Rolla S; Clementi M; Sideri M; Sandri MT; Candiani M
    Eur J Clin Microbiol Infect Dis; 2012 Sep; 31(9):2401-6. PubMed ID: 22382821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papillomavirus testing for triage of women with low-grade squamous intraepithelial lesions.
    Cuzick J; Thomas Cox J; Zhang G; Einstein MH; Stoler M; Trupin S; Behrens CM
    Int J Cancer; 2013 Feb; 132(4):959-66. PubMed ID: 22806936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial.
    Sargent A; Bailey A; Turner A; Almonte M; Gilham C; Baysson H; Peto J; Roberts C; Thomson C; Desai M; Mather J; Kitchener H
    J Clin Microbiol; 2010 Feb; 48(2):554-8. PubMed ID: 20007387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.